Key result
Anthracyclines and ICIs are linked to increased myocardial FDG uptake after chemotherapy.
Why the study?
Cancer therapy-related cardiac dysfunction is an important prognostic factor in breast cancer patients undergoing chemotherapy, motivating evaluation of serial changes in myocardial FDG uptake on routine oncologic PET across chemotherapy regimens.
Does breast cancer chemotherapy (specifically anthracyclines, HER2 inhibitors, and immune checkpoint inhibitors) alter myocardial fluorodeoxyglucose uptake (M-SUR) on routine oncologic PET?
Observational (n=108)
Does breast cancer chemotherapy (specifically anthracyclines, HER2 inhibitors, and immune checkpoint inhibitors) alter myocardial fluorodeoxyglucose uptake (M-SUR) on routine oncologic PET?
Routine oncologic FDG PET detects regimen-specific increases in myocardial metabolic uptake following anthracycline and immune checkpoint inhibitor therapy in breast cancer patients, potentially serving as a marker of chemotherapy-related myocardial metabolic alterations.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“M-SUR reduces individual variability and the influence of blood glucose levels. Using the aorta helps normalize myocardial uptake by accounting for differences in blood glucose and insulin levels at each scan.”
May flag regimen-specific myocardial effects on routine PET; hypothesis-generating for cardiotoxicity monitoring.
OBJECTIVE: Cancer therapy-related cardiac dysfunction is an important prognostic factor in patients with breast cancer undergoing chemotherapy. We evaluated serial changes in myocardial fluorodeoxyglucose (FDG) uptake on routine oncologic PET and assessed whether these changes differed according to chemotherapy regimen. METHODS: We retrospectively analyzed 535 FDG PET examinations obtained before and after chemotherapy in 108 patients with breast cancer. Mean FDG uptake was measured in the myocardium with the highest accumulation and in the descending aorta on the same cross-section, and their ratio was defined as the myocardial standard uptake ratio (M-SUR). Chemotherapy regimens were classified as anthracyclines, human epidermal growth factor receptor 2 (HER2) inhibitors, immune checkpoint inhibitors (ICI), and others. Pre- and post-treatment M-SUR values were compared using the paired t-test. RESULTS: A total of 309 paired examinations were analyzed: anthracyclines, 34 pairs (n = 17); HER2 inhibitors, 146 pairs (n = 40); ICI, 20 pairs (n = 9); and others, 109 pairs (n = 54). M-SUR significantly increased after anthracycline therapy (3.45 ± 2.44 to 5.37 ± 3.67, P = 0.046) and ICI therapy (3.78 ± 2.94 to 4.98 ± 4.27, P = 0.0328). No significant change was observed in the HER2 inhibitor or other regimen groups. CONCLUSION: Serial FDG PET demonstrated regimen-dependent increases in myocardial FDG uptake after anthracycline and ICI therapy. Routine oncologic PET may reflect chemotherapy-related myocardial metabolic alterations.
No takes yet. Share an insight, caveat, or question.
Izoe et al. (2026) conducted an observational in Breast cancer undergoing chemotherapy (n=108). Breast cancer chemotherapy (anthracyclines, HER2 inhibitors, immune checkpoint inhibitors, and others) vs. Pre-treatment baseline and across chemotherapy regimens was evaluated on Myocardial standard uptake ratio (M-SUR) on FDG PET before and after chemotherapy (p=0.046). Anthracycline and immune checkpoint inhibitor chemotherapy increased myocardial FDG standard uptake ratio.
Synapse has enriched 10 related papers. Consider them for comparative context: